NASDAQ$ENGN
enGene Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
enGene reported Q3 2025, revenue of $1.4M, net loss of $29M.
For Q3 2025, enGene reported revenue of $1.4M, a net loss of $29M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $1.4M.
- Net loss $29M.
- enGene MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
Outlook centers on ARR growth, R&D milestones, and cash runway for growth-stage software or biotech.
Tailwinds
- Cybersecurity or pipeline milestones can re-rate the story.
- Subscription or partnership economics improve visibility.
Headwinds
- Operating losses and stock-based compensation persist.
- Financing or trial setbacks could dilute shareholders.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2025
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro